Aptevo Therapeutics Inc. (NASDAQ:APVO) to Post Q3 2024 Earnings of ($0.57) Per Share, Roth Capital Forecasts

Aptevo Therapeutics Inc. (NASDAQ:APVO) – Analysts at Roth Capital boosted their Q3 2024 earnings per share (EPS) estimates for shares of Aptevo Therapeutics in a research note issued to investors on Monday, September 23rd. Roth Capital analyst J. Aschoff now forecasts that the biotechnology company will post earnings per share of ($0.57) for the quarter, up from their previous forecast of ($0.64). The consensus estimate for Aptevo Therapeutics’ current full-year earnings is ($4.30) per share. Roth Capital also issued estimates for Aptevo Therapeutics’ Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($2.97) EPS, FY2025 earnings at ($1.17) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at $0.46 EPS and FY2028 earnings at $0.74 EPS.

Other analysts have also issued research reports about the stock. StockNews.com assumed coverage on shares of Aptevo Therapeutics in a report on Thursday, September 19th. They set a “sell” rating for the company. Roth Mkm dropped their price target on Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a report on Monday.

Aptevo Therapeutics Price Performance

Shares of APVO stock opened at $0.17 on Wednesday. Aptevo Therapeutics has a 12-month low of $0.14 and a 12-month high of $21.56. The firm has a 50-day moving average price of $0.37 and a 200 day moving average price of $1.15.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned approximately 18.36% of Aptevo Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.